. Author manuscript; available in PMC: 2022 Oct 11.

Published in final edited form as: Acta Neuropathol. 2022 Jun 13;144(1):27–44. doi: 10.1007/s00401-022-02444-1

Table 3.

Overall percentage of participants with LATE-NC, stratified by the neuropathologic workups and in the subset of cases with low/no ADNC

	Participants with Braak NFT staging^*	Participants with CERAD neuritic amyloid plaque scores^*	Participants with Braak NFT stages, Thal Aβ phases, and all LATE-NC stages^**

Number of cohorts providing relevant data	13	13	8
Total number of individual participants	5985	6125	3803
Overall LATE-NC% in this group	38.4%	39.4%	38.3%
Criteria for low/no ADNC	Braak NFT stages = 0-II	CERAD score = “none”	Thal Aβ phase = 0
Number of participants with low/no ADNC	1883	1935	787
LATE-NC% in low/no ADNC group	22.4%	27.0%	19.4%

^**